Erratum: Comparative efficacy and safety of adjuvant letrozole versus anastrozole in postmenopausal patients with hormone receptor–positive, node-positive early breast cancer: Final results of the randomized phase iii femara versus anastrozole clinical evaluation (FACE) Trial(2017)35:10 (1041-1048) DOI: 10.1200/JCO.2016.69.2871);Comparative efficacy and safety of adjuvant letrozole versus anastrozole in postmenopausal patients with hormone receptor-positive, node-positive early breast cancer: Final results of the randomized phase III femara versus anastrozole clinical evaluation (FACE) trial

Journal of Clinical Oncology

Volumn 35, Issue 10, 2017, Pages 1041-1048

  Smith, Ian ^a,o   Yardley, Denise ^b   Burris, Howard ^b   De Boer, Richard ^c   Amadori, Dino ^d   McIntyre, Kristi ^f   Ejlertsen, Bent ^h   Gnant, Michael ⁱ   Jonat, Walter ^j   Pritchard, Kathleen I ^k   Dowsett, Mitch ^a   Hart, Lowell ^l   Poggio, Susan ^m   Comarella, Lisa ^e   Salomon, Herve ⁿ   Wamil, Barbara ^m   O'Shaughnessy, Joyce ^f,g  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b SARAH CANNON RESEARCH INSTITUTE   (United States)

^c Western and Royal Melbourne Hospitals   (Australia)

^d DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^e CROS NT   (Italy)

^f TEXAS ONCOLOGY   (United States)

^g BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^h University of Copenhagen   (Denmark)

ⁱ MEDICAL UNIVERSITY OF VIENNA   (Austria)

^j UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^k UNIVERSITY OF TORONTO   (Canada)

^l Sarah Cannon Research Institute/Florida Cancer Specialists   (United States)

^m NOVARTIS PHARMA AG   (Switzerland)

ⁿ NOVARTIS PHARMA K K   (Japan)

^o INSTITUTE OF CANCER RESEARCH   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; LETROZOLE; PROGESTERONE RECEPTOR; TRASTUZUMAB; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ERBB2 PROTEIN, HUMAN; NITRILE; TRIAZOLE DERIVATIVE;

ADJUVANT CHEMOTHERAPY; ADULT; ARTHRALGIA; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER STAGING; CANCER SURVIVAL; CHILD PUGH SCORE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DEPRESSION; DISEASE FREE SURVIVAL; DRUG SAFETY; DYSPNEA; FEMALE; FOLLOW UP; HOT FLUSH; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MYALGIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; X-RAY COMPUTED TOMOGRAPHY; AGED; BREAST NEOPLASMS; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; LYMPH NODE METASTASIS; MASTECTOMY; MIDDLE AGED; PATHOLOGY; SURVIVAL RATE;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; ARTHRALGIA; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DEPRESSION; DISEASE-FREE SURVIVAL; DYSPNEA; FEMALE; HOT FLASHES; HUMANS; HYPERTENSION; LYMPHATIC METASTASIS; MASTECTOMY; MIDDLE AGED; MYALGIA; NEOPLASM STAGING; NITRILES; POSTMENOPAUSE; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL RATE; TRIAZOLES;

EID: 85016616926     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.18.02272     Document Type: Erratum

References (23)

1. Miller WR, Bartlett J, Brodie AM, et al: Aromatase inhibitors: Are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter? Oncologist 13:829-837, 2008
2. World Health Organization: GLOBOCAN 2012. All cancers (excluding non-melanoma skin cancer) estimated incidence, mortality and prevalence worldwide in 2012. http://globocan.iarc.fr/Pages/fact-sheets-cancer.aspx
3. Anderson WF, Chatterjee N, Ershler WB, et al: Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat 76:27-36, 2002
4. Ma CX, Reinert T, Chmielewska I, et al: Mechanisms of aromatase inhibitor resistance. Nat Rev Cancer 15:261-275, 2015
5. National Comprehensive Cancer Network: NCCN clinical practice guidelines in oncology: Breast cancer-v.2. https://www.nccn.org/professionals/physician-gls/f-guidelines.asp
6. Regan MM, Neven P, Giobbie-Hurder A, et al: Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: The BIG 1-98 randomised clinical trial at 8.1 years median follow-up. Lancet Oncol 12:1101-1108, 2011
7. Cuzick J, Sestak I, Baum M, et al: Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 11:1135-1141, 2010
8. Geisler J, Helle H, Ekse D, et al: Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels. Clin Cancer Res 14:6330-6335, 2008
9. Regan MM, Price KN, Giobbie-Hurder A, et al: Interpreting Breast International Group (BIG) 1-98: A randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer. Breast Cancer Res 13:209, 2011
10. Viale G, Regan MM, Dell'Orto P, et al: Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial. Ann Oncol 22:2201-2207, 2011
11. Colleoni M, Giobbie-Hurder A, Regan MM, et al: Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. J Clin Oncol 29:1117-1124, 2011
12. Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group, Forbes JF, Cuzick J, et al: Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9:45-53, 2008
13. Bhatnagar AS, Brodie AMH, Long BJ, et al: Intracellular aromatase and its relevance to the pharmacological efficacy of aromatase inhibitors. J Steroid Biochem Mol Biol 76:199-202, 2001
14. Geisler J, Haynes B, Anker G, et al: Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 20:751-757, 2002
15. Goss PE, Ingle JN, Pritchard KI, et al: Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27-a randomized controlled phase III trial. J Clin Oncol 31:1398-1404, 2013
16. Ellis MJ, Suman VJ, Hoog J, et al: Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: Clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype-ACOSOG Z1031. J Clin Oncol 29: 2342-2349, 2011
17. Rose C, Vtoraya O, Pluzanska A, et al: An open randomised trial of second-line endocrine therapy in advanced breast cancer: Comparison of the aromatase inhibitors letrozole and anastrozole. Eur J Cancer 39:2318-2327, 2003
18. Pfeiler G, Konigsberg R, Hadji P, et al: Impact of body mass index on estradiol depletion by aromatase inhibitors in postmenopausalwomen with early breast cancer. Br J Cancer 109:1522-1527, 2013
19. Ioannides SJ, Barlow PL, Elwood JM, et al: Effect of obesity on aromatase inhibitor efficacy in postmenopausal, hormone receptor-positive breast cancer: A systematic review. Breast Cancer Res Treat 147:237-248, 2014
20. Sestak I, Distler W, Forbes JF, et al: Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: An exploratory analysis from the ATAC trial. J Clin Oncol 28:3411-3415, 2010
21. Lønning PE, Haynes BP, Dowsett M: Relationship of body mass index with aromatisation and plasma and tissue oestrogen levels in postmenopausal breast cancer patients treated with aromatase inhibitors. Eur J Cancer 50:1055-1064, 2014
22. Ewertz M, Gray KP, Regan MM, et al: Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial. J Clin Oncol 30: 3967-3975, 2012
23. Goss PE, Ingle JN, Pritchard KI, et al: Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med 375:209-219, 2016